AstraZeneca's Breztri Approved by US FDA for Asthma, First Triple Therapy for Patients 12+

summarizeSummary

AstraZeneca received US FDA approval for Breztri Aerosphere as the first and only single-inhaler triple therapy for asthma in patients 12 years and older, significantly expanding its market.

check_boxKey Events

• US FDA Approval for Breztri Aerosphere

  Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved by the US FDA for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older.

• First & Only Triple Therapy for Asthma

  Breztri is the first and only single-inhaler fixed-dose triple-combination therapy approved for asthma patients 12 years and older, offering a new treatment option for a large patient population.

• Expanded Market Opportunity

  This approval marks the second indication for Breztri, which was previously approved for COPD, and targets the 27 million people living with asthma in the US, many of whom remain uncontrolled on dual therapies.

• Based on Positive Phase III Trials

  The approval was supported by efficacy and safety data from the Phase III KALOS and LOGOS trials, which demonstrated statistically significant and clinically meaningful improvements in lung function.

auto_awesomeAnalysis

The US FDA approval of Breztri Aerosphere for asthma significantly expands AstraZeneca's market opportunity for this established drug. As the first and only single-inhaler triple therapy for asthma patients aged 12 and older, Breztri gains a competitive advantage in a large market where many patients remain uncontrolled on existing dual therapies. This approval, based on strong Phase III trial data, is expected to drive increased sales and strengthen AstraZeneca's respiratory franchise.